Authors
Latest:
Gautam Jayram, MD, on key bladder cancer agents to keep an eye on"There's a ton of activity in this space, and I think every 6 to 12 months, we're going to keep getting these boluses of information that's going to help us," says Gautam Jayram, MD.
Latest:
Update offers clues to optimal olaparib use in prostate cancerThe latest findings for the PARP inhibitor in prostate cancer come from an analysis of the pivotal phase 3 PROfound trial presented during the 2021 AUA Annual Meeting.
Latest:
Bladder preservation in localized, muscle-invasive bladder cancer: Current state of affairs“In the highly selected patient with localized MIBC, an organ-preserving approach to treatment may produce similar oncologic outcomes to radical surgery with a potential for improved QoL, although there is currently insufficient evidence to recommend bladder preservation therapy as a standard of care," the authors write.
Latest:
Coaching program aims to alleviate female physician burnoutCofounders Adrienne Mann, MD, and Tyra Fainstad, MD, discuss Better Together, a professional, structured coaching program designed to address the burnout experienced by women in medicine.
Latest:
Call for Abstract, Workshop, and Roundtable Submissions for PFD Week 2025Submit your abstract and/or roundtable and workshop proposal for PFD Week 2025, to be held October 14-17 in Vancouver, Canada!
Latest:
Bladder preservation in localized, muscle-invasive bladder cancer: Current state of affairs“In the highly selected patient with localized MIBC, an organ-preserving approach to treatment may produce similar oncologic outcomes to radical surgery with a potential for improved QoL, although there is currently insufficient evidence to recommend bladder preservation therapy as a standard of care," the authors write.
Latest:
Urology PA on how the Surgical Impotence Management Strategy program results in better informed patients"I think that as patients go through this, it's a reminder that it's very scary," says MIchael Jenson, PA-C.
Latest:
Darolutamide linked to fewer hospitalizations in patients with mHSPCCompared with placebo, darolutamide was associated with a numerically lower rate of hospitalizations when combined with androgen-deprivation therapy and docetaxel to treat patients with metastatic hormone-sensitive prostate cancer.
Latest:
Fertility preservation in patients with testicular cancer"Full discussion of the various fertility preservation options and an understanding of the fertility implications of the various treatment modalities must be understood by patients for them to make optimal decisions for their reproductive futures," write the authors.
Latest:
Diversity in Urology: Progress made, but there is more work to be doneKelvin Moses, MD, PhD, interviews Tracy M. Downs, MD, about progress and remaining challenges regarding diversity, equity, and inclusion in the field of urology.
Latest:
Future Directions for Imaging and Biopsy in Prostate CancerThe panel offers key takeaways on the evolving landscape for imaging and biopsy in prostate cancer, highlighting the role for fusion-guided biopsy in the diagnosis and management of prostate cancer.
Latest:
Everything you need to know about medical coding and billing auditsThrough medical claims audits, the practice can help protected itself against fraudulent billing activity and claims.
Latest:
Overview of Advanced/Metastatic Prostate CancerIn the first article of this series, Nilay Gandhi, MD, explains the treatment and management of patients with advanced/metastatic prostate cancer and details the options for androgen deprivation therapy.
Latest:
Tips for physicians to improve work-life balanceOverworking has become the norm, but that doesn’t mean it should be.
Latest:
Case report details spontaneous bladder rupture caused by herpes zoster–associated urinary retentionAlthough cases of acute urinary retention and defecation caused by herpes zoster in the sacral area have been reported, no clinical cases about spontaneous bladder rupture have been previously published, according to the authors.
Latest:
Molecular diagnostic practice in prostate and bladder cancers"Liquid biopsy analysis provides a noninvasive and facile tool for early detection, diagnosis, and recurrence surveillance of urological cancer," writes Jim Lu, MD, PhD.
Latest:
Strategies to mitigate impact of intravenous ICM shortage"The global shortage of ICM has necessitated rapid adaptation of workflows and clinical pathways, which are particularly important for practicing urologists who are evaluating patients for hematuria," write Yair Lotan, MD, and colleagues.
Latest:
Future Perspectives in the Treatment of Patients With Urinary StonesDrs Bechis and Semins discuss future developments in urinary stone management, emphasizing the potential for improved vacuum aspiration devices, combined intravenous and PCNL surgeries, and the hope for medications to dissolve stones.
Latest:
Money Matters: Informing your perspective on the bear marketNo matter what your age or risk tolerance, investing is a lot easier and likely more successful if your perspective is informed by market history.
Latest:
Expert explains challenges of telehealthAlthough much of the discourse around telehealth rightfully focuses on its benefits, the potential drawbacks and limitations are often glossed over, particularly around provider burden.
Latest:
Forward Looking NMIBC Treatment Advancements and Needs in 2024In this final episode, panelists conclude with reflections on the significant progress made in treating NMIBC over the past decade, particularly in the last 5 years. Looking ahead to 2024, experts in urology express excitement about investigational treatments (ie, cretostimogene grenadenorepvec and UGN 102), the potential for personalized medicine, emphasizing the need to understand molecular characteristics of the disease for better treatment customization. The session also highlights the importance of balancing quality of life with effective treatment strategies, and the prospect of utilizing emerging therapies early in the disease process.
Latest:
Ensuring operational continuity is critical with healthcare data breachesWith healthcare data breaches approaching a boiling point, care providers need to adopt an approach that prioritizes operational continuity.
Latest:
Anktiva as a lymphocyte rescue molecule: Unlocking the power of NK cells and T cells"One way to think about how Anktiva works is it is the first molecule, based on the package insert, that increases and proliferates the NK cells, the T cells, and the CD4+ and CD8+ T cells, without up-regulating the suppressive T cells," says Patrick Soon-Shiong, MD.
Latest:
Raveen Syan, MD, shares 2025 Urology on the Beach highlights"I know this year we're going to see even more companies producing more products, more results, and hopefully really help change and improve patient outcomes, especially when it comes to overactive bladder," says Raveen Syan, MD, FPMRS.
Latest:
Frontline Therapy for Non-Metastatic Muscle-Invasive Bladder CancerFrontline treatment approaches recommended by urologists and medical oncologists for patients with non-metastatic muscle-invasive bladder cancer.
Latest:
Camillo Porta, MD, offers key takeaways from CheckMate 9ER trial in renal cell carcinoma"At ASCO GU, we presented the final analysis of the study, which confirmed the superiority of a combination over the TKI monotherapy in terms of both progression-free survival as well as overall survival," says Camillo Porta, MD.
Latest:
Managing aging and frailty in the urologic cancer populationIncreasing numbers of older patients with cancer necessitates adoption of an age-friendly approach to cancer care.
Latest:
Ronney Abaza, MD, FACS, on what’s coming down the pike in robotic surgery“We're really excited as robotic surgeons, because this will be the first time in a couple decades that there'll be competition for robots, and that's only going to make things better,” says Ronney Abaza, MD, FACS.
Latest:
Cretostimogene grenadenorepvec made available through expanded access programCretostimogene grenadenorepvec is an intravesical oncolytic immunotherapy currently under investigation in phase 3 trials.
